Member Info for Inphobe

If you're referring to the Cov96 kit Dave, which I assume you are, BC partnership was not there then. It is now and is a huge achievement, noted at last presentation as subject to sales cycles and lead in, and as we can all see being marketed by BC in multiple regions. But you won't acknowledge that. Was noted back then as at early stages but It'll be coming big imo.

Nonetheless it's CE marked and has been in use. I don't particularly care what was estimated last year Dave. Going to be a good one

To correct AIHL was not marked for end of June, release has not been specified except 'summer'. What we do know is that it is already CE marked, is in the PHE framework and has been proven in the hospital trials at Manchester University NHS Foundation Trust and and Liverpool Women's Hospital.

https://www.lse.co.uk/rns/GDR/antibiotic-induced-hearing-loss-update-58zvvy6rv425ad7.html

I see you're at it again over on AVCT too. Hilarious responses there. As one poster said, 'jog on'.

Sometimes have a look in at advfn for a laugh, some funny **** over there (but Wan's not wrong)

Sure MyLuck, and you mostly sold out apparently last you told us. Want a bit more now I guess, can't blame you. Inveterate bol. Figured what the co's products are yet? Not hearing aids was last clue given.

Guy, we were pointing out that neither Covid or the testing market are 'over'. That's not 'ramping', it's the situation.

I sure wouldn't be here if I didn't believe in what the company's doing, I've made money elsewhere recently (znwd, tgr, kod to name some) but still reckon this is going to be the best play. So please leave out the 'blindly'. You'll find plenty of posters here are being straight when they say they think this is going to come good, that is after all why they're here. You'll also find some of the negative posters who pop in are just trolling or fishing for low entries. Don't be their useful idiot.

Jay, I don't want to be antsy, but you think you're the only one well invested here? Why ***** when plenty of others are similarly invested and post helpfully? As was pointed out in the presentation the BC partnership was at early stage at that time and has to account for sales cycles and lead time. Go view it, it's all there. They've got it marketed now in multiple regions. I think they've got a better handle on it don't you?

As Danaher and pretty much every medical voice has said recently, the testing market's here long term

So no, I somewhat get your frustration (though like rbr said it's better for this board to control it), but I honestly don't get your point

You're somehow confusing a UK political decision (probably inevitable) to open up with what the virus is doing or what the medical profession will be testing for for years. Never mind increased travel

Also, go tell that to India, Nepal, most of Africa, the large clutch of the US that doesn't believe in vaccines and such (yep, one state is offering lottery prizes to try to get people on board) and more

Anyway, as it's been pointed out, just like we test for flu when someone's admitted symptomatic this will have to be tested for in clinical situations worldwide long term.

Seriously Jay? Covid over? Surely you're joking. Where are you? Honestly, nothings missed here, all these products look good long term inc the Covid kits

(much longer term market for clinical tests like PCR imo than LFDs for example, though those too)

We will be testing for this for years, and clinically probably indefinitely as we do for influenza

https://www.bmj.com/content/373/bmj.n1577

Thanks!

Have BC adjusted the EUR & USD pricing on the packs of Cov96 kits recently or have they always been at this level? Can't remember. I think GBP is same as always and EUR may be too, but not sure about USD (currently seems to be at a premium in USD)?

UK GBP 14,950
https://www.mybeckman.uk/reagents/genomic/viral-detection/genedrive-96-sars-cov-2

France EUR 18,240
https://www.beckman.fr/reagents/genomic/viral-detection/genedrive-96-sars-cov-2

US USD 24,000
https://www.beckman.com/reagents/genomic/viral-detection/genedrive-96-sars-cov-2

That would be my take deer (priced in). The mcap is really looking very low for what's on the table now imo. BC and Divoc can do some lifting from here on the Cov96 kits, and the other products are either already or nearly in place.

Well, if the trading update comes when expected and contains any positives, possibly only 3 or 4 trading days left at this level. Just my thoughts. If it doesn't we wait some more, but should be a news rich period ongoing anyway so I'm comfortable enough with that at this stage :)

4/ Good on LSE for removing your post super promptly. What did you expect? Otherwise nice and clean here today

@coldspy

1/ libel
2/ does not at all match that pattern
3/ quit cross-ramping

Yeah, by that reckoning we should see something by end of this week or Mon.

What is interesting is that we're currently priced for delays/no sales. Having already taken the big drop and then slide to this (very low for commercial stage imo) mcap, I see little downside with current portfolio of products & partnerships in place and lots of upside. Good place to be approaching trading update from I think (negative already priced in, any positive will boost now).

Article by Kanav Kahol just tweeted by Divoc

https://www.cnbctv18.com/healthcare/indias-diagnostics-industry-opportunity-or-challenge-9694131.htm

No, it was undervalued before and still is. The acquisition of the remaining 50% not only means full ownership of project but pushes it forward massively. And if you can't see what's coming in this location in this sector then can't help you

Oh, imo definitely a market for shipping especially those festering cruise ships I'd have thought!

Hi longrun, there's a few interesting reads on point of care around (one posted below, I was actually looking for another I saw a while back & will post if I find)

Target as I see it is anywhere highly accurate test is needed where sending a sample to lab is inconvenient, untimely, or not possible. So surgeries, hospital admission/triage, remote or undeveloped locations (latter similar targets for HCV and TB pocs).

For transport may be offered privately at ports for those whose destination requires who haven't yet had a lab test and cannot wait for a lab result? Hard to quantify but it would seem there could be significant demand in that?

(I think I read your question as asking about testing everyone travelling, and I don't think I see that as its role, but happy to be wrong)

https://www.nature.com/articles/s41431-021-00816-x